Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Krystal BiotechFRA:4KB +2.00%55 Equity-to-Asset is 0.91 as of Jun. 2026, which is 3% below its 10-year median of 0.94. GuruFocus rates FRA:4KB with a GF Score™ of 55/100 and a GF Value™ of €279.04 (Fairly Valued). The stock has 2 warning signs investors should review. Among 1,411 Biotechnology companies, Krystal Biotech ranks better than 85.54% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Krystal Biotech's Total Stockholders Equity for the quarter that ended in Jun. 2026 was €1,179.7 Mil. Krystal Biotech's Total Assets for the quarter that ended in Jun. 2026 was €1,302.6 Mil.
Therefore, Krystal Biotech's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.91.
The historical rank and industry rank for Krystal Biotech's Equity-to-Asset or its related term are showing as below:
FRA:4KB'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.13 Med: 0.94 Max: 0.99
Current: 0.91
During the past 10 years, the highest Equity to Asset Ratio of Krystal Biotech was 0.99. The lowest was 0.13. And the median was 0.94.
FRA:4KB's Equity-to-Asset is ranked better than 85.54% of 1411
companies
in the Biotechnology industry
Industry Median: 0.68
vs FRA:4KB: 0.91
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Krystal Biotech Equity-to-Asset Related Terms
Krystal Biotech Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Krystal Biotech's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:4KB vs NUVL, HALO, APGE: Equity-to-Asset Comparison
For the Biotechnology subindustry, Krystal Biotech's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Krystal Biotech Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Krystal Biotech's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Krystal Biotech's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Krystal Biotech's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Krystal Biotech (FRA:4KB) has a Equity-to-Asset of 0.91 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Krystal Biotech and its competitors. This is near median its historical median of 0.94. Over the past decade, Krystal Biotech's Equity-to-Asset has ranged from 0.13 to 0.99. According to the industry distribution chart, Krystal Biotech ranks #204 out of 1411 companies in the Biotechnology industry, placing it in the top 14.5%.
Is Krystal Biotech's Equity-to-Asset too high?
Krystal Biotech's current Equity-to-Asset of 0.91 is near median its 10-year median of 0.94. Over the past 10 years, this metric has ranged from a low of 0.13 to a high of 0.99. The Biotechnology industry median Equity-to-Asset is 0.68. Krystal Biotech's value of 0.91 is 33.8% above this industry median. Based on the distribution chart, Krystal Biotech ranks #204 out of 1411 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Krystal Biotech has a GF Score™ of 55/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Krystal Biotech's Equity-to-Asset compare to NUVL and HALO?
According to the Biotechnology industry distribution chart, Krystal Biotech ranks #204 out of 1411 companies for Equity-to-Asset. This places Krystal Biotech in the top 15% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.68. Krystal Biotech's value of 0.91 is 33.8% above this benchmark. Historically, Krystal Biotech's own Equity-to-Asset has ranged from 0.13 to 0.99 over the past decade. While the company's 10-year median is 0.94 vs. the industry median of 0.68, Krystal Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Krystal Biotech's current Equity-to-Asset of 0.91 is 33.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Krystal Biotech and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Krystal Biotech's current Equity-to-Asset is 0.91, which is near median its own 10-year median of 0.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Krystal Biotech stock overvalued right now?
Based on GuruFocus' analysis, Krystal Biotech (FRA:4KB) is currently considered Fairly Valued. The stock's GF Value™ is €279.04, compared to a current price of €281.00 — trading 0.7% above its estimated fair value. The current Equity-to-Asset is 0.91, which is near median its 10-year median of 0.94 and 33.8% above the Biotechnology industry median of 0.68. Krystal Biotech's overall GF Score™ is 55/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Krystal Biotech (FRA:4KB), the current Equity-to-Asset is 0.91 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Krystal Biotech (FRA:4KB) Overvalued in 2026?
Based on GuruFocus' analysis, Krystal Biotech stock appears to be overvalued.
The current stock price of €281.00 is trading 0.7% above its estimated GF Value™ of €279.04.
GuruFocus considers Krystal Biotech to be Fairly Valued.
Key valuation signals for FRA:4KB:
Equity-to-Asset: 0.91 (near median its 10-year median of 0.94)
GF Value™: €279.04 vs. price of €281.00 (0.7% above fair value)
Industry Position: 33.8% above the Biotechnology median (#204 of 1411)
No single metric tells the full story. See the FRA:4KB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
55GF Score
Get the complete analysis for FRA:4KB
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4KB has been successfully added to your 
